Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.6.99.1 (
NADPH-diaphorase
)
3,903
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A striking heterogeneous distribution of topographic and cellular
huntingtin
immunoreactivity was observed within the human neostriatum using three distinct
huntingtin
antibodies. Patchy areas of low
huntingtin
immunoreactivity were present in both the caudate nucleus and putamen, surrounded by an intervening area of greater immunoreactivity. Comparison of
huntingtin
immunoreactivity with contiguous serial sections stained for enkephalin and calbindin D28k immunoreactivities showed that the topographic heterogeneity of
huntingtin
immunostaining corresponded to the patch (striosome) and matrix compartments within the striatum. Huntingtin immunoreactivity was confined primarily to neurons and neuropil within the matrix compartment, whereas little or no neuronal or neuropil
huntingtin
immunostaining was observed within the patch compartment. There was marked variability in the intensity of
huntingtin
immunolabel among medium-sized striatal neurons, whereas a majority of large striatal neurons were only faintly positive or without any immunoreactivity. Combined techniques for
NADPH-diaphorase
enzyme histochemistry and
huntingtin
immunocytochemistry, as well as double immunofluorescence for either nitric oxide synthase or calbindin D28k in comparison with
huntingtin
expression, revealed a striking correspondence between calbindin D28k and
huntingtin
immunoreactivities, with little or no colocalization between
NADPH-diaphorase
or nitric oxide synthase neurons and
huntingtin
expression. These observations suggest that the selective vulnerability of spiny striatal neurons and the matrix compartment observed in Huntington's disease is associated with higher levels of
huntingtin
expression, whereas the relative resistance of large and medium-sized aspiny neurons and the patch compartments to degeneration is associated with low levels of
huntingtin
expression.
...
PMID:Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. 909 40
The mechanism by which polyglutamine expansion in Huntington's disease (HD) results in selective neuronal degeneration remains unclear. We previously reported that the immunohistochemical distribution of N-terminal
huntingtin
in HD does not correspond to the severity of neuropathology, such that significantly greater numbers of
huntingtin
aggregates are present within the cortex than in the striatum. We now show a dissociation between
huntingtin
aggregation and the selective pattern of striatal neuron loss observed in HD. Aggregate formation was predominantly observed in spared interneurons, with few or no aggregates found within vulnerable spiny striatal neurons. Multiple perikaryal aggregates were present in almost all cortical
NADPH-diaphorase
neurons and in approximately 50% of the spared
NADPH-diaphorase
striatal neurons from early grade HD cases. In severe grade HD patients, aggregates were more prominent as nuclear inclusions in
NADPH-diaphorase
neurons, with less perikaryal and neuropil aggregation. In contrast, nuclear or perikaryal
huntingtin
aggregates were present in less than 4% of the vulnerable calbindin striatal neurons in all HD cases. These findings support the hypothesis that polyglutamine aggregation may not be a predictor of cell loss. Rather than a harbinger of neuronal death, mutant
huntingtin
aggregation may be a cytoprotective mechanism against polyglutamine-induced neurotoxicity.
...
PMID:Huntington aggregates may not predict neuronal death in Huntington's disease. 1058 36
In Huntington's disease (HD), corticostriatal and striatopallidal projection neurons preferentially degenerate as a result of mutant
huntingtin
expression. Pathological deficits in nitric oxide (NO) signaling have also been reported in corticostriatal circuits in HD, however, the impact of age and sex on nitrergic transmission is not well characterized. Thus, we utilized
NADPH-diaphorase
(NADPH-d) histochemistry and qPCR assays to assess neuronal NO synthase (nNOS) activity/expression in aged male and female Q175 heterozygous mice. Compared to age-matched controls, male Q175 mice exhibited reductions in NADPH-d staining in the motor cortex at 21, but not, 16 months of age. Comparisons across genotypes showed that striatal NADPH-d staining was significantly decreased at both 16 and 21 months of age. Comparisons within sexes in 21 month old mice revealed a decrease in striatal NADPH-d staining in males, but no changes were detected in females. Significant correlations between cortical and striatal NADPH-d staining deficits were also observed in males and females at both ages. To directly assess the role of constitutively active NOS isoforms in these changes, nNOS and endothelial NOS (eNOS) mRNA expression levels were examined in R6/2 (3 month old) and Q175 (11.5 month old) mice using qPCR assays. nNOS transcript expression was decreased in the cortex (40%) and striatum (54%) in R6/2 mice. nNOS mRNA down-regulation in striatum of Q175 animals was more modest (19%), and no changes were detected in cortex. eNOS expression was not changed in the cortex or striatum of Q175 mice. The current findings point to age-dependent deficits in nNOS activity in the HD cortex and striatum which appear first in the striatum and are more pronounced in males. Together, these observations and previous studies indicate that decreases in nitrergic transmission progress with age and are likely to contribute to corticostriatal circuit pathophysiology particularly in male patients with HD.
...
PMID:Age- and sex-related changes in cortical and striatal nitric oxide synthase in the Q175 mouse model of Huntington's disease. 3052 13